Replimune Group, Inc.
NASDAQ:REPLBiotechnology
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
Volume 2.13M
Average 7.51M
REPL Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Replimune Group, Inc.NASDAQ: REPL
Other Income / Expenses · Q3 FY2026 · quarter ended Dec 2025
Other income / expenses growth accelerates
Q3 FY2026 other income / expenses of $627K rose 146.9% year over year, ahead of the -20.2% change in trailing-twelve-month other income / expenses. Sequentially, it fell 47.4% from the prior quarter. Over 3 fiscal years it compounded at +276.2% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +146.9% holds above the trailing-twelve-month pace of -20.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 14.8M USD
- Year-over-year change
- -23.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 14.8M | -23.7% |
| FY2024 | 2024-03-31 | 19.39M | +528.6% |
| FY2023 | 2023-03-31 | 3.08M | +1009.4% |
| FY2022 | 2022-03-31 | 278K | +130.4% |
| FY2021 | 2021-03-31 | (915K) | — |
Other Income / Expenses vs competitors
How REPL compares with its peers on the latest reported figures
- REPL's LTM Dec 2025 other income / expenses of $10.64M is the 4th highest of the 11 companies compared; the peer median is $5.14M.
- Its year-over-year change of -20.2% is the 6th highest of 10, against a peer median of -20.1%.
- Over three fiscal years its annual growth of +276.2% compares with a peer median of +35.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $54.3M | +157.6% | — | 43.8% | |
| LTM Mar 2026 | $42.51M | +18.6% | +121.9% | 196.7% | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
| LTM Dec 2025 | $10.64M | -20.2% | +276.2% | — | |
| LTM Sep 2026 | $8.6M | -33.8% | +20.0% | 2.3% | |
| LTM Mar 2026 | $5.75M | -2.2% | +37.4% | 16.2% | |
| LTM Jun 2024 | $4.52M | — | -7.1% | 554.5% | |
| LTM Mar 2026 | $4.18M | -19.6% | +32.8% | 5.8% | |
| LTM Mar 2026 | -$7.37M | -116.5% | — | 4.7% | |
| LTM Mar 2026 | -$54.54M | -309.6% | — | 175948.4% | |
| LTM Sep 2026 | -$835.68M | -850.2% | — | 457.7% | |
| Peer median (excluding REPL) | $5.14M | -20.1% | +35.1% | 30.0% | |
Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.14M | 4.58M | 0 | 0 | 0 |
| Gross Profit | (4.14M) | (4.58M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 57.49M | 80.65M | 126.53M | 174.96M | 189.45M |
| Selling, General & Admin | 21.13M | 36.26M | 0 | 0 | 0 |
| Operating Expenses | 78.62M | 116.91M | 177.08M | 234.77M | 261.63M |
| Depreciation & Amortization | 4.14M | 4.58M | 2.45M | 5.08M | 5.93M |
| EBITDA | (76.48M) | (114.41M) | (171.72M) | (227.77M) | (253.92M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (82.76M) | (121.48M) | (177.08M) | (234.77M) | (261.63M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 916K | 390K | 10.01M | 23.36M | 21.12M |
| Interest Expense | 3.06M | 2.22M | 4.16M | 6.66M | 7.89M |
| Other Income / Expenses | (915K) | 278K | 3.08M | 19.39M | 14.8M |
| Income Before Tax | (83.68M) | (121.21M) | (174M) | (215.39M) | (246.83M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.81M) | (3.17M) | 288K | 408K | 468K |
| Net Income | (80.87M) | (118.04M) | (174.28M) | (215.79M) | (247.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| EPS (Diluted) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| Weighted Avg Shares | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
| Weighted Avg Shares (Diluted) | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
Replimune Group, Inc.
NASDAQ:REPL
Intrinsic Alpha fair value
Locked
Current Price
$19.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.